UK life sciences venture capital firm Syncona is launching bio Therapeutics with a £ 34 m ( $ 43 m ) investment . The start - up will seek to develop regulatory T cell therapy to treat immune cell diseases . Quell will develop immune cell therapies for non - cancer diseases , including type 1 diabetes , chronic arthritis and inflammatory kidney disease , as well as solid organ transplant rejection .
UK life sciences venture capital firm Syncona is launching Quell Therapeutics with a £34m ($43m) investment. The start-up will seek to develop regulatory T cell therapies to treat immune system diseases. Quell will use immune cell therapies for non-cancer diseases, including type 1 diabetes, rheumatoid arthritis and inflammatory bowel disease, as well as solid organ transplant rejection.